Jaeb Center for Health Research
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Jaeb Center for Health Research sits in the top decile of US sponsors by registered trial count (#218 of 15,742 sponsors by registered trial count).
Jaeb Center for Health Research: 119 sponsored US clinical trials, 17 recruiting.
Jaeb Center for Health Research sponsors 119 registered US clinical trials on ClinicalTrials.gov, 17 of them currently recruiting, and 89 completed. 53 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Amblyopia, with 9 trials.
Top-decile sponsor footprint
Jaeb Center for Health Research ranks in the top decile of sponsors by registered trial count (#218 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
89 of 95 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
119 total, page 1 of 3
A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control
NCT07095894
A Study of Uveitis in Children <18 Years of Age
NCT07518134
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
NCT06837181
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
NCT06790784
Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery
NCT06880835
CGM for the Early Detection and Management of Hyperglycemia in Pregnancy
NCT06957028
Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes
NCT06535789
T1D Pregnancy & Me
NCT06959316
Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age
NCT06524882
Bionic Pancreas in CFRD
NCT06449677
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
NCT06380517
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
NCT05844982
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
NCT05904028
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
NCT05589714
Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM
NCT05145491
Fenofibrate for Prevention of DR Worsening
NCT04661358
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
NCT04378790
Gyrate Atrophy Ocular and Systemic Study
NCT05312736
Evaluation of Tonabersat for DME
NCT05727891
Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF
NCT05639556
Bevacizumab Treatment For Type 1 ROP
NCT04634578
Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F
NCT04765345
Rate of Progression in EYS Related Retinal Degeneration
NCT04127006
Rate of Progression in USH2A-related Retinal Degeneration
NCT03146078
Loop T2D Observational Study
NCT05951569
Full-Time Occlusion Therapy for Intermittent Exotropia in Children
NCT05462821
Time in Glucose Hospital Target
NCT05135676
A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP
NCT04634604
Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)
NCT04016662
Virtual Diabetes Specialty Clinic: A Study Evaluating Remote Initiation of Continuous Glucose Monitoring
NCT04765358
Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes
NCT04233034
The Insulin-Only Bionic Pancreas Pivotal Trial
NCT04200313
Base-in Prism Spectacles for Intermittent Exotropia
NCT03998670
A Pilot Study Evaluating Photobiomodulation Therapy for Diabetic Macular Edema
NCT03866473
Surgical Idiopathic Intracranial Hypertension Treatment Trial
NCT03501966
The Loop Observational Study
NCT03838900
Effects of Pneumatic Vitreolysis on Macular Hole
NCT03677869
Effects of Pneumatic Vitreolysis on Vitreomacular Traction
NCT03647267
Low-Dose Atropine for Treatment of Myopia
NCT03334253
CGM Intervention in Teens and Young Adults With Type 1 Diabetes (T1D)
NCT03263494
PROMINENT-Eye Ancillary Study (Protocol AD)
NCT03345901
DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME
NCT03321513
Wireless Innovation for Seniors With Diabetes Mellitus
NCT03240432
Day and Night Closed-loop in Young People With Type 1 Diabetes
NCT02925299
Binocular Dig Rush Game Treatment for Amblyopia
NCT02983552
Strategies to Enhance New CGM Use in Early Childhood (SENCE)
NCT02912728
Trial of Overminus Spectacle Therapy for Intermittent Exotropia
NCT02807350
Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
NCT02858076
Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents
NCT02714972
Anti-VEGF Treatment for Prevention of PDR/DME
NCT02634333
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 18 |
| Phase 3 | 46 |
| Phase 4 | 7 |
Where Jaeb Center for Health Research enrollment is open (later-stage tilt)
17 recruiting of 119 indexed (14% open); 89 completed (75%).
Phase mix: 53 late (III/IV) vs 21 early (I/II) (later-stage heavy).
Top condition: Amblyopia (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Jaeb Center for Health Research: open-pipeline peers nationwide
Peers matched on 119 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Jaeb Center for Health Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 119 trials (± recruiting share)
- Children's Hospital Los Angeles · 119 trials · 29% recruiting
- Medtronic - MITG · 119 trials · 4% recruiting
- Michigan State University · 120 trials · 20% recruiting
- San Diego State University · 118 trials · 27% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
- Alaska Blind Child Discovery · 14% recruiting · 7 trials
Related
What to do with this Jaeb Center for Health Research page
119 registered trials is a research-attention snapshot, not an endorsement of Jaeb Center for Health Research or any single study.
- 17 of Jaeb Center for Health Research's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Amblyopia is the condition Jaeb Center for Health Research studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Amblyopia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Jaeb Center for Health Research pipeline card: 119 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.